STRATEC Biomedical Systems AG / Final Results/Preliminary Results
24.03.2010 07:06
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
STRATEC reports substantial sales and earnings growth in 2009
Birkenfeld, March 24, 2010
STRATEC Biomedical Systems AG, Birkenfeld, Germany, (Frankfurt: SBS; Prime
Standard) today published the preliminary consolidated figures of the
STRATEC Group for the 2009 financial year as of December 31, 2009 in
accordance with IFRS (International Financial Reporting Standards).
|[![CDATA[|[pre|]]]|]
Key Figures (EUR 000s) 01/01/-12/31/2009 01/01/-12/31/2008 Change
Sales 79,589 60,971 + 30.5%
Overall performance 87,228 67,646 + 28.9%
EBITDA 17,292 13,510 + 28.0%
EBIT 14,719 11,225 + 31.1%
Consolidated net income 11,674 8,206 * + 42.3%
Earnings per share (EUR) 1.03 0.72 * + 43.1%
EBIT margin (%) 18.5 18.4
|[![CDATA[|[/pre|]]]|]
* Excluding a non-operating one-off expense of around Euro 2.1 million due
to a valuation adjustment in 2008. Including this expense, 'Consolidated
net income' in 2008 amounts to Euro 6.1 million and 'Earnings per share' to
Euro 0.54.
STRATEC increased its sales by 30.5% from Euro 61.0 million to Euro 79.6
million in the 2009 financial year. Sales were therefore above the upper
end of the guidance range forecast by the company (Euro 73.2 million to
Euro 79.3 million). Despite having four development projects simultaneously
in the ramp-up phase towards serial production for the first time in its
history, STRATEC was still able to increase its EBIT margin to 18.5% in
2009 (previous year: 18.4%). The company's guidance range for the EBIT
margin was 18.5% to 19.5%.
Including temporary personnel, the STRATEC Group had a total of 380
employees as of December 31, 2009 (previous year: 284).
In the 2010 financial year, STRATEC expects to generate sales in a range of
Euro 96 million to Euro 102 million. Growth in the EBIT margin will be
driven by the serial production of four major development programs and an
increasing share of sales generated from consumables and replacement parts.
STRATEC expects the EBIT margin to rise by at least 0.5% points compared to
the 2009 figure.
Based on stable developments in all current programs, as well as the
prospects and customer forecasts for the new programs, STRATEC expects to
achieve consistent growth in the coming years. Specifically, a compound
annual growth rate (CAGR) of more than 15% is expected for sales between
2010 and 2012.
Forthcoming publication dates
The final approved figures for the 2009 financial year will be published on
April 13, 2010 and will be discussed in the annual results teleconference
for analysts, investors and press representatives. The 2009 Annual Report
will also be available for downloading from the company's internet site on
April 13, 2010.
The Annual General Meeting of STRATEC Biomedical Systems AG will be held in
Pforzheim on Friday, May 21, 2010. The invitation to the Annual General
Meeting will be forwarded to STRATEC shareholders via their depositing
banks in good time ahead of the Annual General Meeting.
The interim report as of March 31, 2010 will be published on April 28,
2010.
About STRATEC
STRATEC Biomedical Systems AG (www.stratec-biomedical.de) designs and
manufactures fully automated systems for its partners in the fields of
clinical diagnostics and biotechnology. These partners market such systems,
in general together with their own reagents, to laboratories, blood banks
and research institutes around the world. The company develops its products
on the basis of its own patented technologies. Shares in the company (ISIN:
DE0007289001) are traded in the Prime Standard segment of the Frankfurt
Stock Exchange.
The STRATEC Group consists of the publicly listed parent company STRATEC
Biomedical Systems AG and of subsidiaries and second-tier subsidiaries in
Germany, the USA, the UK, Switzerland and Romania.
Further information can be obtained from:
STRATEC Biomedical Systems AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916 190
Fax: +49 7082 7916 999
E-mail: ir@stratec-biomedical.de
24.03.2010 07:06 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Medienarchiv at |[![CDATA[|[a href="http://www.dgap-medientreff.de"|]www.dgap-medientreff.de|[/a|]]]|] and |[![CDATA[|[a href="http://www.dgap.de"|]www.dgap.de|[/a|]]]|]
---------------------------------------------------------------------------
Language: English
Company: STRATEC Biomedical Systems AG
GewerbestraÃe 37
75217 Birkenfeld
Deutschland
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec-biomedical.de
Internet: www.stratec-biomedical.de
ISIN: DE0007289001
WKN: 728900
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in München, Düsseldorf, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: STRATEC reports substantial sales and earnings growth in 2009
| Source: EQS Group AG